Document is current

Article History

Accepted: 12 December 2024

First Online: 25 January 2025

Declarations

:

: The LINC 3 and LINC 4 studies were conducted in accordance with the Declaration of Helsinki, and study protocols were approved by independent ethics committees/institutional review boards.

: Patients provided written informed consent to participate at the start of the core and extension phases of the studies.

: Patients provided written informed consent for their data to be published anonymously.

: MF reports grants to her university from Crinetics and Sparrow and occasional scientific consulting fees from Crinetics, Recordati Rare Diseases, Sparrow, and Xeris Pharmaceuticals; she served as a member of the LINC 3 steering committee and is a member of the editorial board of Pituitary. RP has received research funding from Recordati AG, Corcept Therapeutics, Xeris Pharmaceuticals (Strongbridge), Neurocrine Biosciences, and Spruce Biosciences and has served as a consultant for Corcept Therapeutics, Recordati AG, Crinetics Pharmaceuticals, and H Lundbeck A/S. JN-P reports research grants and consultancy payments to his university from Crinetics, Diurnal, HRA Pharma, and Recordati Rare Diseases. MRG has received speaker fees from Recordati, Ipsen, Novo Nordisk, and Camurus and attended advisory boards for Novo Nordisk, Recordati, and Crinetics Pharmaceuticals. BMKB reports occasional consulting honoraria from H Lundbeck A/S, Recordati Rare Diseases, Sparrow, and Xeris Pharmaceuticals; she served on the LINC 3 steering committee. RJA reports grants and personal fees from Xeris Pharmaceuticals, Spruce Biosciences, Neurocrine Biosciences, Corcept Therapeutics, Diurnal Ltd, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, and Recordati Rare Diseases and personal fees from Adrenas Therapeutics, Quest Diagnostics, H Lundbeck A/S, Novo Nordisk, and Besins Pharmaceuticals. RF reports consultancy for Corcept Therapeutics and Recordati and research grants from Strongbridge and Corcept Therapeutics. AS reports serving as a speaker and consultant for Recordati; he was also a member of the LINC 3 steering committee. PW reports receiving travel grants and speaker fees from Novartis, Ipsen, Recordati, Novo Nordisk, Strongbridge Biopharma, Merck-Serono, Lilly, and Berlin Chemie. MB reports consultancy for and travel grants from Recordati. AP is an employee of Recordati. AMP was an employee of Recordati at the time the analyses were conducted. AL reports grants and personal consulting fees from Novartis, Recordati, Pfizer, and Corcept Therapeutics.